The company has requested the Shareholders to update their respective BO account with 12 digits e-TIN number, BO account, address, mobile number, e-mail address etc. through their respective DPs before the Record Date.

The company hereby informs its shareholders and stakeholders that the Company will make an investment of BDT 250 crore in oncology production facility 2. Upon completion, annual production capacity will increase by 37.97 crore tablets, 21.10 crore capsules, 2.53 crore blisters and 2 crore vials injectable. The investment is expected to have a positive impact on the Company's revenue. The Company will strengthen its R&D capabilities to enhance the regulatory readiness of its own drugs for SRA markets. Through rigorous research, product optimization and compliance with international quality standards, the Company will prepare its products for stringent regulatory assessment and approval.

There will be no price limit on the trading of the shares of the Company today (17.10.2026) following its corporate declaration.

The Board of Directors has recommended 11% Cash Dividend for the year ended June 30, 2026. Date of AGM: 13.12.2026, Time: 11:00 AM, Venue: Digital Platform subject to approval from BSEC. Record Date: 10.11.2026. The Company has also reported EPS of Tk. 8.41, NAV per share of Tk. 35.83 and NOCFPS of Tk. 9.68 for the year ended June 30, 2026 as against Tk. 4.10, Tk. 28.86 and Tk. 6.93 respectively for the year ended June 30, 2025. (cont.1) EPS, NAV & NOCFPS: For the year ended 30 June 2026, the audited financial statements of Beacon Pharmaceuticals PLC show earnings per share (EPS) more than doubling to BDT 8.41 from BDT 4.10 (+105.19%), driven mainly by 30.96% higher sales. (cont.2) Net asset value (NAV) per share rose 24.14% to BDT 35.83 from BDT 28.86, as retained earnings strengthened shareholders' equity. Net operating cash flow per share (NOCFPS) increased 39.76% to BDT 9.68 from BDT 6.93, on higher receipts from customers and others.

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 15, 2026 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2026.

The company has informed that Mr. Anindya Sarkar FCS has been appointed as the Company Secretary of the Company with effect from 01.09.2026.

The Company has informed that Mr. Md. Emroj Hossain will hold the Current Charge of the responsibilities of Company Secretary of the company with effect from July 01, 2026.

(Q3 Un-audited): EPS was Tk. 1.22 for January-March 2026 as against Tk. 0.28 for January-March 2025; EPS was Tk. 5.95 for July 2025-March 2026 as against Tk. 3.75 for July 2024-March 2025. NOCFPS was Tk. 9.45 for July 2025-March 2026 as against Tk. 5.45 for July 2024-March 2025. NAV per share was Tk. 33.55 as on March 31, 2026 and Tk. 28.86 as on June 30, 2025. Reasons for deviation: Revenue growth in the prior year was constrained due to socio-political factors, which also impacted operating cash flows. However, in the current year's third quarter, the company has recovered and achieved strong revenue growth. As a result, improved cash collections have led to a notable increase in NOCFPS, reflecting better operational performance and liquidity compared to the same period last year.

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 27, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.

(Q2 Un-audited): EPS was Tk. 2.47 for October-December 2025 as against Tk. 1.91 for October-December 2024; EPS was Tk. 4.73 for July-December 2025 as against Tk. 3.47 for July-December 2024. NOCFPS was Tk. 6.57 for July-December 2025 as against Tk. 6.38 for July-December 2024. NAV per share was Tk. 32.32 as on December 31, 2025 and Tk. 28.86 as on June 30, 2025.